Market Place
Sourcing Support
All News #Library
Biotech
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50
23 Oct 2023 //
GLOBENEWSWIRE
Ambrx Provides Safety and Efficacy Data from Phase 1/2 APEX-01 Trial of ARX517
16 Oct 2023 //
GLOBENEWSWIRE
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
26 Sep 2023 //
GLOBENEWSWIRE
Ambrx to Present Preliminary ARX517 First-in-Human Safety Data at ESMO 2023
28 Jul 2023 //
GLOBENEWSWIRE
FDA Grants Fast Track Designation for Ambrx™s ARX517
19 Jul 2023 //
GLOBENEWSWIRE
Ambrx Soars on Synthetic ADC Linker Science
10 Jul 2023 //
SDBJ
Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Meeting
27 Mar 2023 //
GLOBENEWSWIRE
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 Achieves Positive Results
01 Mar 2023 //
BUSINESSWIRE
ARX517 Shows Encouraging Data in Patients with Advanced Prostate Cancer
16 Feb 2023 //
BUSINESSWIRE
Ambrx to host Investor Day to Discuss ARX788 and ARX517 in Cancer
13 Feb 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.